Advances in Radiation Oncology最新文献

{"title":"Neoadjuvant Cemiplimab Followed by Radiation for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report","authors":"Colton Betts BS , Matthew Maxwell BSA , Mark Floyd MD , Jamie Pawlowski MD","doi":"10.1016/j.adro.2024.101529","DOIUrl":"https://doi.org/10.1016/j.adro.2024.101529","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 8","pages":"Article 101529"},"PeriodicalIF":2.3,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424000927/pdfft?md5=436d3681fa948c9272eae76de6aadd5a&pid=1-s2.0-S2452109424000927-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141324942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monocentric Retrospective Study: Efficacy, Feasibility, and Prognostic Factors of Single-Insertion High-Dose-Rate Brachytherapy With 4 Sessions for Locally Advanced Cervical Cancer","authors":"Lucie Houdou MD ,&nbsp;Claire Meynard MD ,&nbsp;Sophie Guillerm MD ,&nbsp;Camille Mimoun MD ,&nbsp;Tiphaine Lambert MD ,&nbsp;Eva Marchand MD ,&nbsp;Diane Jornet MD ,&nbsp;Ingrid Fumagalli MD ,&nbsp;Laurent Quero MD, PhD ,&nbsp;Cyrille Huchon MD, PhD ,&nbsp;Christophe Hennequin MD, PhD","doi":"10.1016/j.adro.2024.101512","DOIUrl":"https://doi.org/10.1016/j.adro.2024.101512","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aims to assess the feasibility and efficacy of high-dose rate (HDR) brachytherapy (BT) administered in a single insertion with 4 treatment sessions for locally advanced cervical cancer and to identify the prognostic factors influencing outcomes.</p></div><div><h3>Methods and Materials</h3><p>We retrospectively analyzed the clinical data of patients with cervical cancer with locally advanced disease (International Federation of Gynecology and Obstetrics 2018 IB-IVB) treated at our institution from January 2014 through December 2021. Each patient received definitive radiation therapy with an external irradiation dosage between 45 and 50.4 Gy along with concurrent chemotherapy. HDR-BT (24 Gy) was prescribed to a high-risk clinical target volume.</p></div><div><h3>Results</h3><p>One hundred thirty-nine patients were included and the HDR-BT program could be fully performed in 136 patients (98%). Over a median follow-up duration of 40.5 months, the 2-year local control (LC), overall survival (OS), and disease-free survival rates stood at 79.4%, 77.7%, and 61.7%, respectively, with 5-year rates at 78.2%, 61.6%, and 55.7%. Multivariate analysis revealed the primary determinant of LC as the tumor's response to external beam radiation therapy as determined via magnetic resonance imaging before BT. Parametrial involvement demonstrated a significant multivariate association with disease-free survival (<em>P</em> = .04). Regarding OS, parametrial invasion (<em>P</em> = .01) and the tumor's response postchemoradiotherapy (<em>P</em> = .02) emerged as significant factors. Regarding chronic toxicities, 18% (25 patients) experienced grade 3 complications. An optimal D2 cc (bowel) threshold of 70 Gy (<em>P</em> = .001) was identified to limit chronic digestive complications of grade 3 or higher.</p></div><div><h3>Conclusions</h3><p>The implementation of single-insertion, 4-session HDR-BT could be performed in 98% of the patients. It yields favorable LC and OS rates, coupled with tolerable toxicity in patients with locally advanced cervical cancer. Response to initial chemoradiotherapy evaluated on pre-BT magnetic resonance imaging is an important prognostic factor and could help to individualize therapeutic strategies.</p></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101512"},"PeriodicalIF":2.3,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424000757/pdfft?md5=6a1134f0b6afab43627741e98e94322b&pid=1-s2.0-S2452109424000757-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141243505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Horizons in Radiation Therapy Auto-Contouring: Distilling Insights, Embracing Data-Centric Frameworks, and Moving Beyond Geometric Quantification","authors":"Kareem A. Wahid PhD ,&nbsp;Carlos E. Cardenas PhD ,&nbsp;Barbara Marquez ,&nbsp;Tucker J. Netherton PhD, DMP ,&nbsp;Benjamin H. Kann MD ,&nbsp;Laurence E. Court PhD ,&nbsp;Renjie He PhD ,&nbsp;Mohamed A. Naser PhD ,&nbsp;Amy C. Moreno MD ,&nbsp;Clifton D. Fuller MD, PhD ,&nbsp;David Fuentes PhD","doi":"10.1016/j.adro.2024.101521","DOIUrl":"https://doi.org/10.1016/j.adro.2024.101521","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101521"},"PeriodicalIF":2.3,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424000848/pdfft?md5=a18e1dbcee6143ab5b9162d2990beded&pid=1-s2.0-S2452109424000848-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141067988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Local Treatment in Combination with Systemic Therapy for Advanced Esophageal Cancer: A Systematic Review and Meta-analysis","authors":"Jianrui Ji MD ,&nbsp;Yunsong Liu MD ,&nbsp;Yongxing Bao MD ,&nbsp;Yu Men MD ,&nbsp;Jun Wang MD ,&nbsp;Zhouguang Hui MD","doi":"10.1016/j.adro.2024.101522","DOIUrl":"10.1016/j.adro.2024.101522","url":null,"abstract":"<div><h3>Purpose</h3><p>Initial studies investigating the combination of local and systemic treatments in advanced esophageal cancer (EC) have conflicting conclusions regarding survival benefits. The objective of this systematic review and meta-analysis is to assess the efficacy of the addition of local therapy to systemic treatments in patients with advanced EC.</p></div><div><h3>Methods and Materials</h3><p>A systematic literature search was conducted in the PubMed, EMBASE, and CENTRAL databases. Key eligibility criteria included studies that enrolled patients with histologically confirmed EC or esophagogastric junction cancer with metastasis or recurrence and compared survival benefits between the combined local and systemic treatment group and the systemic treatment alone group. Survival outcomes, represented by hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS), were pooled using a random effects model. The MINORS score was adopted for quality assessment. Risk of bias was statistically examined by Begg's and Egger's tests.</p></div><div><h3>Results</h3><p>A total of 1 randomized controlled trial (RCT) and 10 qualified retrospective studies including 14,489 patients were identified. Addition of local therapy to systemic treatment significantly improved PFS (HR, 0.52; 95% CI, 0.37-0.73; <em>P</em> &lt; .001) and OS (HR, 0.69; 95% CI, 0.58-0.81; <em>P</em> &lt; .0001) compared with systemic treatment alone. The subgroup analysis revealed that combined local and systemic treatment conferred a significant survival advantage in both patients with oligometastasis (PFS: HR, 0.45; 95% CI, 0.31-0.64; <em>P</em> &lt; .0001; OS: HR, 0.62; 95% CI, 0.48-0.79; <em>P</em> &lt; .0001) and recurrence (OS: HR, 0.55; 95% CI, 0.37-0.81; <em>P</em> = .002).</p></div><div><h3>Conclusions</h3><p>In conclusion, addition of local treatment to systemic therapy can improve survival in patients with advanced EC, particularly in those with oligometastasis or recurrent diseases.</p></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101522"},"PeriodicalIF":2.3,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S245210942400085X/pdfft?md5=916b4ddd7619004389754d7cfdaefc6d&pid=1-s2.0-S245210942400085X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Feasibility of Stereotactic Radiosurgery for Patients with 15 or more Brain Metastases","authors":"Rituraj Upadhyay MD ,&nbsp;Joshua D. Palmer MD ,&nbsp;Brett G. Klamer PhD ,&nbsp;Haley K. Perlow MD ,&nbsp;Jonathan E. Schoenhals MD ,&nbsp;Jayeeta Ghose PhD ,&nbsp;Prajwal Rajappa MD ,&nbsp;Dukagjin M. Blakaj MD, PhD ,&nbsp;Sasha Beyer MD, PhD ,&nbsp;John C. Grecula MD ,&nbsp;Austin J. Sim MD, JD ,&nbsp;Lanchun Lu PhD ,&nbsp;Wesley Zoller CMD ,&nbsp;James B. Elder MD ,&nbsp;Arnab Chakravarti MD ,&nbsp;Evan Thomas MD, PhD ,&nbsp;Raju R. Raval MD, DPhil","doi":"10.1016/j.adro.2024.101509","DOIUrl":"10.1016/j.adro.2024.101509","url":null,"abstract":"<div><h3>Background</h3><p>Current standard of care treatment for patients with ≥15 brain metastases (BM) is whole brain radiation therapy (WBRT), despite poor neurocognitive outcomes. We analyzed our institutional experience of treating these patients with stereotactic radiosurgery (SRS), with the aim of evaluating safety, cognitive outcomes, and survival metrics.</p></div><div><h3>Methods</h3><p>Patients who received SRS for ≥15 BMs in 1 to 5 fractions from 2014 to 2022 were included. Cognitive outcomes were objectively evaluated using serial Patient-Reported Outcome Measurement Information System (PROMIS) scores. The Kaplan-Meier method was used for survival analysis and log-rank test for intergroup comparisons.</p></div><div><h3>Results</h3><p>Overall, 118 patients underwent 124 courses of LINAC-based SRS. The median number of lesions treated per course was 20 (range, 15-94). Most patients received fractionated SRS to a dose of 24 Gy in 3 fractions (81.5%). At the time of SRS, 19.4% patients had received prior WBRT, and 24.2% had received prior SRS. The rate of any grade radiation necrosis (RN) and grade ≥3 RN were 15.3% and 3.2%, respectively. When evaluating longitudinal PROMIS score trends, 25 of 31 patients had a stable/improved PROMIS score. Patients who did not receive prior brain RT had a longer median survival (7.4 months vs 4.6 months, <em>P</em> = .034). The 12m local control was 97.6%, and the cumulative incidence of distant intracranial failure, with death as a competing event, was 46% (95% CI, 36%, 55%). One year freedom from neurologic death, leptomeningeal disease, and salvage WBRT were 89%, 94.6%, and 84%, respectively.</p></div><div><h3>Conclusion</h3><p>We present here one of the largest studies evaluating SRS for patients with ≥15 BMs. SRS was safe, had favorable cognitive outcomes, and had comparable survival outcomes to contemporary studies evaluating WBRT in this population. Treatment-naïve patients had a median survival of &gt;6 months, long enough to benefit from cognitive sparing with SRS. Our study supports randomized studies comparing SRS and hippocampal avoidance WBRT approaches for these patients.</p></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101509"},"PeriodicalIF":2.3,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424000721/pdfft?md5=a6c8f2b132b244cf5b2247cb44206c9d&pid=1-s2.0-S2452109424000721-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140765018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence Potential Impact on Resident Physician Education in Radiation Oncology","authors":"Neil D. Almeida MD ,&nbsp;Rohil Shekher MD ,&nbsp;Abigail Pepin MD ,&nbsp;Tyler V. Schrand BS ,&nbsp;Victor Goulenko MD ,&nbsp;Anurag K. Singh MD ,&nbsp;Simon Fung-Kee-Fung MD","doi":"10.1016/j.adro.2024.101505","DOIUrl":"10.1016/j.adro.2024.101505","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101505"},"PeriodicalIF":2.3,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S245210942400068X/pdfft?md5=1101df2abe680c9a09b46c27c9847e98&pid=1-s2.0-S245210942400068X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140789642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation Therapy Delivery During the 2023 Israel-Hamas War: Trust Prevails Over Fear","authors":"Leora Brazg Ferro MD ,&nbsp;Benjamin W. Corn MD, FASTRO ,&nbsp;Gil Goldzweig PhD ,&nbsp;Myriam Sultan MBA ,&nbsp;Efrat Shekel MSc ,&nbsp;Eli Sapir MD","doi":"10.1016/j.adro.2024.101514","DOIUrl":"10.1016/j.adro.2024.101514","url":null,"abstract":"<div><h3>Purpose</h3><p>The attack by Hamas on Israeli civilians (October 7, 2023) triggered the ongoing war, which could be detrimental to cancer care in general and radiation therapy (RT) in particular. To assure continuity of care within the Radiation Oncology Department of Samson Assuta Ashdod University Hospital (SAAUH), which borders on Gaza, patient-centric measures were redoubled by our institution. This study describes the impact of these measures on patients' perception and their willingness to continue RT, despite fear of war.</p></div><div><h3>Methods and Materials</h3><p>A survey questionnaire was designed to detect changes in attitude and treatment adherence during war. It was offered to the patients undergoing RT at SAAUH. A Pearson correlation between the items relating to desire to continue the therapy was calculated. Smallest space analysis was conducted to illustrate the association between the variables.</p></div><div><h3>Results</h3><p>Forty-seven patients enrolled in this study reported a significantly lower feeling of personal safety during wartime in comparison with the confidence in the professionalism of the staff (paired samples <em>t</em> test, t(43) = 4.61; <em>P</em> &lt; .001). Simultaneously, patients perceived that the impact of the national situation on their health was very low (mean of 1.59 on a scale of 1-6). Both the Pearson correlation test and smallest space analysis revealed that the desire to continue treatment in general and to continue treatment at the same department were significantly related to trust in the staff's professionalism.</p></div><div><h3>Conclusions</h3><p>Fear of war can pose a major pitfall in providing daily RT care. This obstacle may be potentially overridden by creating deep, trusting relationships between the patients and the medical staff.</p></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101514"},"PeriodicalIF":2.3,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424000770/pdfft?md5=950ae0fea565fe44a19977b45b838f23&pid=1-s2.0-S2452109424000770-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140758978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Presenting With Intravascular Tumor Emboli in Axillary Soft Tissue: Recurrence Risk and Radiation Therapy Outcomes","authors":"Reith R. Sarkar MD ,&nbsp;Jessica A. Lavery PhD ,&nbsp;Zhigang Zhang PhD ,&nbsp;Boris A. Mueller MD, MPH ,&nbsp;Melissa Zinovoy MD ,&nbsp;John J. Cuaron MD ,&nbsp;Beryl McCormick MD ,&nbsp;Atif J. Khan MD ,&nbsp;Simon N. Powell MD, PhD ,&nbsp;Hannah Y. Wen MD ,&nbsp;Lior Z. Braunstein MD","doi":"10.1016/j.adro.2024.101508","DOIUrl":"10.1016/j.adro.2024.101508","url":null,"abstract":"<div><h3>Purpose</h3><p>Intravascular tumor emboli in axillary soft tissue (ITE) is a rare pathologic finding in breast cancer and is associated with higher axillary nodal disease burden. The independent prognostic and predictive value of this entity is unknown, as is the role of radiation therapy for ITE.</p></div><div><h3>Methods and Materials</h3><p>We analyzed a prospectively maintained database of breast cancer patients treated from 1992 to 2020. Patients with ITE were matched to those without (1:2) based on propensity scores to control for potential confounding factors. Locoregional (LRR) and distant recurrence (DR) were evaluated using competing risks methods accounting for death as a competing event. Overall survival (OS) and disease-free survival (DFS) were evaluated by Cox regression models. Among patients with ITE, we also evaluated whether RT improved outcomes.</p></div><div><h3>Results</h3><p>Among 2377 total patients, 129 had ITE, of whom 126 were propensity score matched to 252 without ITE. Median follow-up from time of surgery was 5.5 years (IQR 2.3, 9.7). There were no statistically significant differences in the 5-year incidence of LRR between groups (5.4% [95% CI, 1.6%-13%] with ITE vs 10% [95% CI, 6.7%-15%] without, <em>P</em> = .53) or DR (24% [95% CI, 15% 35%] with ITE vs 21% [95% CI, 16%-27%] without, <em>P</em> = .51). Five-year OS and DFS did not differ between groups (<em>P</em> &gt; .9 for both comparisons, patients with ITE vs without ITE). In analyzing the effect of RT among patients with ITE, receipt of RT was associated with significantly improved DFS (HR, 0.34, 95% CI, 0.12-0.93, <em>P</em> = .04).</p></div><div><h3>Conclusions</h3><p>Patients with ITE do not exhibit significantly worse LRR, DR, DFS, or OS compared with a propensity-score-matched cohort without ITE. However, among patients with ITE, those who received RT demonstrated significantly improved DFS. Larger studies with longer follow-up are needed to evaluate the prognostic and predictive implications of ITE.</p></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101508"},"PeriodicalIF":2.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S245210942400071X/pdfft?md5=47c2e30164dab6b586630c523e193388&pid=1-s2.0-S245210942400071X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140792474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic Body Radiation Therapy and Concurrent Targeted Therapy for Lung Metastases in Pediatric Sarcoma","authors":"Riley M. Goldsmith BS ,&nbsp;Jessica L. Xing MD ,&nbsp;Cory W. Heal MD ,&nbsp;Michelina C. De La Maza MD ,&nbsp;Baldassarre Stea MD, PhD","doi":"10.1016/j.adro.2024.101517","DOIUrl":"10.1016/j.adro.2024.101517","url":null,"abstract":"<div><h3>Purpose</h3><p>The purpose of this investigation was to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) for pulmonary metastases from pediatric sarcomas.</p></div><div><h3>Methods and Materials</h3><p>This study was a single institutional retrospective chart review including patients younger than 21 years of age at diagnosis who had received SBRT for pulmonary metastasis from metastatic sarcoma. Our current electronic record system was queried for all eligible patients. Primary endpoint was tumor response as defined by Respone Evaluation Criteria in Solid Tumors 1.1 criteria. Secondarily, we analyzed factors that affected tumor response as well as toxicity of treatment. Median dose was 50 Gy ranging from 30 to 60 Gy in 5 fractions to the planning tumor volume.</p></div><div><h3>Results</h3><p>There were 7 patients, ranging in age from 6 to 21 years with a total of 14 pulmonary lesions treated with SBRT. Median and mean follow-up times for the 7 patients were 10.6 months and 15.9 months, respectively. The complete response rate was 50%, partial response 21%, stable disease 21%, and progressive disease 7%. Four of the 7 patients were treated with concurrent systemic therapy, 3 of which were targeted oral therapies. Additionally, we observed that patients who were on targeted therapy such as regorafenib or pazopanib seemed to have better local control compared with patients without targeted therapy.</p></div><div><h3>Conclusions</h3><p>With an overall response rate of 92%, SBRT provided a noninvasive effective palliative treatment option with few side effects in this small retrospective study of 7 patients. A larger prospective clinical trial is warranted to evaluate the role of SBRT in the treatment of unresectable metastatic pediatric sarcomas.</p></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101517"},"PeriodicalIF":2.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424000800/pdfft?md5=511e55f1bf347c6f745ac0f34af63edc&pid=1-s2.0-S2452109424000800-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140768766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokine Release Syndrome in a Patient With Metastatic Triple-Negative Breast Cancer Treated With Hypofractionated Radiation Therapy, Who Had Previously Undergone Immunotherapy: A Case Report","authors":"Jee Suk Chang MD, PhD ,&nbsp;Jee Hung Kim MD, PhD","doi":"10.1016/j.adro.2024.101513","DOIUrl":"10.1016/j.adro.2024.101513","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 7","pages":"Article 101513"},"PeriodicalIF":2.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424000769/pdfft?md5=b0ac97fe4068f731405cecfdf17dae57&pid=1-s2.0-S2452109424000769-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}